BIA responds to the publication of the NICE Methods Review consultation paper

Responding to the publication of a consultation paper on the National Institute for Health and Care Excellence (NICE) Methods following a review, Steve Bates OBE, Chief Executive of the Bioindustry Association said: 

"The proposed changes to NICE's methods published today send an important signal to the innovative biotech sector that the UK is serious about ensuring access to new medicines. We are very encouraged by the focus on removing significant barriers to access, which puts the UK on a new footing, setting the benchmark for health technology appraisals - particularly around modifiers, uncertainty and discounting. It will help ensure both that industry can continue to deliver innovative medicines and that patients can access them". 

Charlie Galvin, Chair of the BIA Rare Disease Industry Group and General Manager of Amicus Therapeutics said: 

“Today’s proposals send a welcome signal that more NHS patients could benefit from cutting edge medicines. We are encouraged to see the progress that has been made and the recognition that more needs to be done to ensure we address the challenges for rare disease.”

“If we get this right, the changes outlined could make a meaningful difference to the lives of people across the UK living with rare diseases.”  

“We look forward to working with NICE to ensure that these proposals develop into tangible changes that can transform the lives of patients.”


Notes to Editors

1. For more information please contact Jack Fellows, Communications and Media Manager on or 07825942934

About the BIA 

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.